ReviewFrontiers in immunology2026
The regulatory roles of dysregulated lactate dehydrogenase A in anti-tumor immunity within immune cells.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Post-translational modifications in CD8Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Malignant tumors maintain proliferative, invasive, and metastatic capacities through metabolic reprogramming. Lactate dehydrogenase A (LDHA), is an essential glycolytic enzyme that is aberrantly overexpressed in diverse human malignancies. The enzymatic activity of LDHA is tightly modulated by multiple post-translational modifications, including acetylation, phosphorylation, and lactylation. LDHA promotes the Warburg effect and lactate accumulation, while participating in tumor DNA damage repair, malignant progression, and drug resistance. LDHA and its metabolite lactate substantially modulate the differentiation and functional status of tumor-infiltrating immune cells, including lymphoid and myeloid cells. These metabolic changes remodel the tumor immune microenvironment and regulate anti-tumor immune responses in a context-dependent manner. This review systematically summarizes the regulatory mechanisms of LDHA in immune cell metabolism and anti-tumor immunity. Additionally, it discusses the clinical potential of LDHA as a promising anti-tumor therapeutic target and explores the application prospects of combining LDHA inhibitors with immunotherapies, such as chimeric antigen receptor T-cell (CAR-T) therapy and immune checkpoint blockade. This study aims to provide novel perspectives for the research and development of tumor targeted therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.